Chengdu's leading partner Bio Age launches phase II clinical trial of NLRP 3 inhibitor BGE-102
The official WeChat public account of Chengdu HitGen Drug Development Co., Ltd. (hereinafter referred to as "Chengdu HitGen") announced that the company's partner BioAgeLabs, Inc. (hereinafter referred to as "BioAge", Nasdaq stock code: BIOA) recently launched the Phase II proof-of-concept clinical trial QUELL-CV of BGE-102 and completed the administration of the first subject.
The official WeChat public account of Chengdu HitGen Drug Development Co., Ltd. (hereinafter referred to as "Chengdu HitGen") announced that the company's partner BioAgeLabs, Inc. (hereinafter referred to as "BioAge", Nasdaq stock code: BIOA) recently launched the Phase II proof-of-concept clinical trial QUELL-CV of BGE-102 and completed the administration of the first subject. It is reported that BGE-102 is a potent, structurally novel, and brain-penetrating oral small molecule NLRP3 inhibitor. Its lead compounds were screened through the DNA-Encoded Compound Library (DEL) technology platform of HitGen. Li Jin, Chairman and CEO of Chengdu HitGen, said: "BGE-102 has entered Phase II clinical research, which further proves the ability of our company's DEL technology platform to screen novel small molecules for challenging targets. It also once again reflects the advantages of our company's cooperation model with BioAge. We will continue to deepen our cooperation and look forward to seeing the subsequent development progress of BGE-102." According to reports, Chengdu Pioneer has successively produced a number of research and development results since entering into cooperation with BioAge. In April 2021, the two parties jointly announced the successful screening of promising compounds with development potential; in February 2024, the two parties jointly published a paper in the journal "Bioorganic & Medicinal Chemistry Letters" titled The Discovery of Noveland Potentinda zoleNLRP3inhibitorsenabledbyDNA-encodedlibraryscreening ("Using DEL technology to discover novel, efficient, electroneutral small molecule inhibitors of the important target NLRP3"), after which the two parties jointly submitted a patent application for the novel structural compounds discovered by DEL screening. Relying on the world's leading DEL core technology platform and a series of derivative new drug R&D technology platforms, Chengdu Pioneer has created a unique new drug "seed" discovery "engine" to provide therapeutic molecules and new tool molecules to the global pharmaceutical industry. The company's DEL platform has an entity molecular library containing more than 1.2 trillion DNA-encoded compounds. DEL products and efficient screening capabilities have served new drug discovery projects in multiple institutions and organizations around the world. By the end of 2025, the company has empowered thousands of innovative drug research and development projects for more than 600 customers around the world. Currently, the cooperation between HitGen and BioAge continues to advance, and both parties will rely on HitGen's DEL technology platform to carry out drug discovery research on more new targets. (